Country: United States
Language: English
Source: NLM (National Library of Medicine)
BUDESONIDE (UNII: Q3OKS62Q6X) (BUDESONIDE - UNII:Q3OKS62Q6X)
Golden State Medical Supply
ORAL
PRESCRIPTION DRUG
Budesonide extended-release tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Budesonide extended-release tablets are contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of budesonide extended-release tablets. Anaphylactic reactions have occurred with other budesonide formulations [see Adverse Reactions (6.2)]. Risk Summary Limited published studies report on the use of budesonide in pregnant women; however, the data are insufficient to inform a drug-associated risk for major birth defects and miscarriage. There are clinical considerations (see Clinical Considerations). In animal reproduction studies with pregnant rats and rabbits, subcutaneous administration of budesonide during organogenesis at doses 0.5 times and 0.05 times, respectively, the maximum recommended human dose, resulted in increased fetal loss, decreased pup weights, and skele
Budesonide extended-release tablets 9 mg, are white, round, biconvex, film-coated tablets imprinted with “ WPI ” and “ 2510 ” on one side and plain on the other. Tablets are supplied in bottles of 30, NDC 51407-224-30. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from light and moisture.
Abbreviated New Drug Application
BUDESONIDE- BUDESONIDE TABLET, FILM COATED, EXTENDED RELEASE GOLDEN STATE MEDICAL SUPPLY ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION BUDESONIDE EXTENDED-RELEASE TABLETS. THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BUDESONIDE EXTENDED-RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BUDESONIDE EXTENDED-RELEASE TABLETS. BUDESONIDE EXTENDED-RELEASE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1997 INDICATIONS AND USAGE Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. ( 1) DOSAGE AND ADMINISTRATION The recommended dosage for the induction of remission in adult patients with active, mild to moderate ulcerative colitis is one 9 mg tablet to be taken once daily in the morning with or without food for up to 8 weeks. ( 2.1) DOSAGE FORMS AND STRENGTHS Extended-release tablets: 9 mg ( 3) CONTRAINDICATIONS Known hypersensitivity to budesonide or any of the ingredients in budesonide extended-release tablets ( 4) WARNINGS AND PRECAUTIONS Hypercorticism and adrenal suppression: Since budesonide extended-release tablets are a glucocorticosteroid, follow general warnings concerning glucocorticoids. ( 5.1) Transferring patients from systemic glucocorticoids: Risk of impaired adrenal function when transferring from glucocorticoid treatment with higher systemic effects to glucocorticoid treatment with lower systemic effects, such as budesonide extended-release tablets. Taper patients slowly from systemic corticosteroids if transferring to budesonide extended-release tablets. ( 5.2) Immunosuppression: Potential worsening of infections (e.g., existing tuberculosis, fungal, bacterial, viral, or parasitic infection; or ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients. ( 5.3) ADVERSE REACTIONS Most common adverse reactions (incidence greater than or eq Read the complete document